Thioredoxin and aging: What have we learned from the survival studies?

Madeline G. Roman, Lisa C. Flores, Geneva M. Cunningham, Christie Cheng, Colton Allen, Gene B Hubbard, Yidong Bai, Thomas L. Saunders, Yuji Ikeno

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

Our laboratory has conducted the first systematic survival studies to examine the biological effects of the an-tioxidant protein thioredoxin (Trx) on aging and age-related pathology. Our studies with C57BL/6 mice over-expressing Trx1 [Tg(act-TRX1)+/0 and Tg(TXN)+/0] demonstrated a slight extension in early lifespan compared to wild-type (WT) mice; however, no significant effects were observed in the later part of life. Overexpression of Trx2 in male C57BL/6 mice [Tg(TXN2)+/0] demonstrated a slightly extended lifespan compared to WT mice. The pathology results from two lines of Trx1 transgenic mice showed a slightly higher incidence of age-related neoplastic diseases compared to WT mice, and a slight increase in the severity of lymphoma, a major neoplas-tic disease, was observed in Trx2 transgenic mice. Together these studies indicate that Trx overexpression in one compartment of the cell (cytosol or mitochondria alone) has marginal beneficial effects on lifespan. On the other hand, down-regulation of Trx in either the cytosol (Trx1KO) or mitochondria (Trx2KO) showed no significant changes in lifespan compared to WT mice, despite several changes in pathophysiology of these knockout mice. When we examined the synergetic effects of overexpressing Trx1 and Trx2, TXNTg x TXN2Tg mice showed a significantly shorter lifespan with accelerated cancer development compared to WT mice. These results suggest that synergetic effects of Trx overexpression in both the cytosol and mitochondria on aging are deleterious and the development of age-related cancer is accelerated. On the other hand, we have recently found that down-regulation of Trx in both the cytosol and mitochondria in Trx1KO x Trx2KO mice has beneficial effects on aging. The results generated from our lab along with our ongoing study using Trx1KO x Trx2KO mice could elucidate the key pathways (i.e., apoptosis and autophagy) that prevent accumulation of damaged cells and genomic instability leading to reduced cancer formation.

Original languageEnglish (US)
Pages (from-to)126-133
Number of pages8
JournalAging Pathobiology and Therapeutics
Volume2
Issue number3
DOIs
StatePublished - 2020

Keywords

  • Thioredoxin
  • aging
  • cancer
  • knockout mouse
  • lifespan
  • transgenic mouse

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Cellular and Molecular Neuroscience
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Thioredoxin and aging: What have we learned from the survival studies?'. Together they form a unique fingerprint.

Cite this